about
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.Heparin-induced hyperkalemia after cardiac surgery.Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMACastleman's disease associated with myasthenia gravis.Heparin is much more than just an anticoagulant.Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction.Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor.Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation mCharacteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1.A spontaneous ductal aneurysm presenting with left recurrent laryngeal nerve palsyClinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgeryUterus didelphys associated with left renal agenesis presenting as a pelvic kidney with contralateral ureteric obstruction
P50
Q30665387-3AA05335-2930-4C53-81D7-D4118C932382Q33345383-6989AB9D-0070-460A-9733-E48B55EE23F0Q34217697-76473EE2-88AA-4BFE-85D8-5B59048B478AQ35123319-C03DDCA4-9E3B-4FB5-BD32-F915C118EDA3Q35671290-CC81D4FF-3E9B-446E-82BF-5F997BB64367Q36588682-3C6F6A4B-9B65-43FE-948E-2DE9ECDFBF38Q46920946-85522A56-96C7-4746-81C7-03A4481B3A74Q47755598-3D551AB0-3BA6-4D0E-B787-1ECB46DB41BCQ53508468-7E8CB5CA-55B2-464A-B1B9-B016223BD199Q53641630-BB2D4404-608C-44FD-9210-7C5FE050DB3EQ74408404-0539DE5C-8820-4574-81BE-3661315209F8Q80357639-93C0CFD7-BB3B-43A6-8E93-50E7EE9166B5Q80926656-3822D3A7-65CA-41C9-8AFE-BA304A388A03
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jonathan Day
@ast
Jonathan Day
@en
Jonathan Day
@es
Jonathan Day
@nl
type
label
Jonathan Day
@ast
Jonathan Day
@en
Jonathan Day
@es
Jonathan Day
@nl
prefLabel
Jonathan Day
@ast
Jonathan Day
@en
Jonathan Day
@es
Jonathan Day
@nl
P106
P21
P31
P496
0000-0002-0955-3176